ASSURE Touts Positive Clinical Results for its Wearable Cardioverter Defibrillator

Kestra Medical Technologies claims its ASSURE Wearable Cardioverter Defibrillator (WCD) system is effective at reducing false-positive shock alarms, citing results of the ASSURE WCD Clinical Evaluation – Detection and Safety Study (ACE-DETECT, NCT 03887052) published in the Journal of Cardiovascular Electrophysiology.¹
 
WCDs provide lifesaving protection for patients at elevated risk of sudden cardiac death (SCD). The ASSURE WCD was designed to enhance comfort, provide actionable insights to healthcare providers, and to increase patient confidence and wear time compliance while protecting them from SCD during a period of elevated risk.
 
The objective of the ACE-DETECT study was to evaluate the ambulatory detection performance of the ASSURE WCD. The study enrolled 130 adult cardiac patients who wore the WCD for a 30-day assessment period. Significantly lower false positive shock alarm rates occurred with the ASSURE WCD (one every 1,333 days) compared with the performance criteria set for the study (one every 3.4 days). In addition, no true ventricular tachycardia (VT) or ventricular fibrillation (VF) events were missed by the ASSURE WCD. The device also demonstrated low patient‐reported discomfort, high wear time compliance, low inappropriate detection rates, and mostly mild adverse events.
 
“Until now, clinicians have had only one option for WCDs to protect their at-risk patients,” said Brian Webster, CEO. “We are excited to bring a new modern WCD system to the market and are extremely pleased with our clinical results.”
 
In an invited editorial, Dr. Niraj Varma, M.D., Ph.D., professor of Medicine at the Cleveland Clinic Lerner College of Medicine and Consultant Cardiologist at the Cleveland Clinic, London, commented about the study results, writing “These results, meeting the prespecified goals of the study, represent a significant advance over contemporary technology and are attributable to improvements in garment structure and sensing algorithm ” adding that patient experience was positive regardless of gender and notied that “Significantly, more than three-quarters of the patients crossing over from the commercially available WCD to the test device expressed greater satisfaction with the novel garment.”
 
The ASSURE WCD System by Kestra received U.S. Food and Drug Administration premarket approval July 28, 2021, and is protecting cardiac patients in multiple cities across America as the company continues its product launch and expansion. 
 
Kestra Medical Technologies Inc. is a privately held wearable medical device and digital healthcare company that protects cardiac patients with diagnostic monitoring and therapeutic technologies. Kestra was founded in 2014 by leaders from the external (AED) and internal (ICD) defibrillation industries. Based in Kirkland, Wash., Kestra is a portfolio company of Bain Capital, an alternative investment firm with deep global experience in healthcare.

Reference 
¹ Poole JE, Gleva MJ, Birgersdotter-Green U, et al. A wearable cardioverter defibrillator with a low false alarm rate. J Cardiovasc Electrohpysiol. 2022;1-12. Doi:10.1111/jce.15417